enGene Therapeutics Inc. Stock Price

NasdaqCM:ENGN Community·US$108.5m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
5 Fair Values set on narratives written by author

Create Narrative

ENGN Share Price Performance

US$1.62

-1.69 (-51.06%)

US$1.62

-1.69 (-51.06%)

US$1.62

Sun, 14 Jun 26

Share Pricen/a

ENGN Community Narratives

There are no narratives available yet.

Create Narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Excellent balance sheet with slight risk.

4 Risks

1 Reward

View Full Analysis

enGene Therapeutics Inc. Key Details

Last Reported Earnings

Jan 31, 2026

Next Reporting Earnings

n/a

: -1.83
: 0%
: 0%
: 8.9%

View Full Analysis

About ENGN

Founded: n/a
Employees: 82
CEO: Ronald H. Cooper
WebsiteView website: www.engene.com

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.